Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAllogene Therapeutics Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 5 | -$0.24 | -$0.18 | -$0.21 |
| Q2 2026 | 1 | -$0.22 | -$0.22 | -$0.22 |
| Q3 2026 | 1 | -$0.22 | -$0.22 | -$0.22 |
| Q4 2026 | 1 | -$0.22 | -$0.22 | -$0.22 |
Allogene Therapeutics Inc Earnings Date And Information
Allogene Therapeutics Inc last posted its earnings results on Thursday, November 6th, 2025. The company reported $-0.19 earnings per share for the quarter, topping analysts' consensus estimates of $-0.23 by $0.04. The company had revenue of 0 for the quarter and had revenue of 22.00 K for the year. Allogene Therapeutics Inc has generated $-1 earnings per share over the last year ($-1.32 diluted earnings per share) and currently has a price-to-earnings ratio of -2.15. Allogene Therapeutics Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Allogene Therapeutics Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2025 | Q3 2025 | -$0.23 | -$0.19 | 0.04 | $2.50 K | $0 |
| 08/13/2025 | Q2 2025 | -$0.28 | -$0.23 | 0.05 | $2.50 K | $0 |
| 05/13/2025 | Q1 2025 | -$0.28 | -$0.28 | 0 | N/A | $0 |
| 03/13/2025 | Q4 2024 | -$0.34 | -$0.28 | 0.06 | N/A | $0 |
| 11/07/2024 | Q3 2024 | -$0.34 | -$0.32 | 0.02 | $10.77 K | $0 |
| 08/07/2024 | Q2 2024 | -$0.35 | -$0.35 | 0 | $2.01 M | $0 |
| 05/13/2024 | Q1 2024 | -$0.38 | -$0.38 | 0 | N/A | $22.00 K |
| 03/14/2024 | Q4 2023 | -$0.47 | -$0.51 | -0.04 | N/A | $-44,000 |
| 11/02/2023 | Q3 2023 | -$0.53 | -$0.37 | 0.16 | N/A | $22.00 K |
| 08/02/2023 | Q2 2023 | -$0.59 | -$0.54 | 0.05 | N/A | $22.00 K |
| 05/03/2023 | Q1 2023 | -$0.63 | -$0.68 | -0.05 | N/A | $30.00 K |
| 02/28/2023 | Q4 2022 | -$0.71 | -$0.66 | 0.05 | N/A | $47.00 K |
| 11/02/2022 | Q3 2022 | -$0.62 | -$0.58 | 0.04 | N/A | $49.00 K |
| 08/09/2022 | Q2 2022 | -$0.61 | -$0.52 | 0.09 | N/A | $86.00 K |
| 05/04/2022 | Q1 2022 | -$0.59 | -$0.56 | 0.03 | N/A | $61.00 K |
| 02/23/2022 | Q4 2021 | -$0.61 | -$0.54 | 0.07 | N/A | $51.00 K |
| 11/04/2021 | Q3 2021 | -$0.56 | -$0.57 | -0.01 | N/A | $49.00 K |
| 08/04/2021 | Q2 2021 | -$0.55 | -$0.53 | 0.02 | N/A | $44.00 K |
| 05/05/2021 | Q1 2021 | -$0.48 | -$0.25 | 0.23 | N/A | $38.35 M |
| 02/25/2021 | Q4 2020 | -$0.56 | -$0.53 | 0.03 | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Allogene Therapeutics Inc Earnings: FAQ's
In the previous quarter, Allogene Therapeutics Inc (:ALLO) reported $-0.19 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.23 by $0.04.
The conference call for Allogene Therapeutics Inc's latest earnings report can be listened to online.
The conference call transcript for Allogene Therapeutics Inc's latest earnings report can be read online.
Allogene Therapeutics Inc (:ALLO) has a recorded annual revenue of $22.00 K.
Allogene Therapeutics Inc (:ALLO) has a recorded net income of $-257,590,000.Allogene Therapeutics Inc has generated $-1.32 earnings per share over the last four quarters.
Allogene Therapeutics Inc (:ALLO) has a price-to-earnings ratio of -2.15 and price/earnings-to-growth ratio is -0.18.